VCBeat Health

🚀 Forget "Cheap China." The era of "#Innovation Dawn" is here. 摩根士丹利's latest #report isn't just an upgrade—it's a fundamental re-rating of #ChineseBiotech. The #data speaks volumes: ✅$34B → $220B: Projected annual revenue from #drugs originating in China by 2030 to 2040 ✅5% → 35%: Projected share of U.S. FDA approvals for China-developed drugs The driving forces? A mature innovation ecosystem, proven cost advantages, and pipelines rapidly closing the gap with the West. Read the full #insight to understand what this means for your #strategy 👉 https://lnkd.in/e_3mDKxF #Capital #Investment #Healthcare #VCBeat

🚀 New #data reveals that the total #value of China's Innovative drug out-licensing #deals has surged past $100 billion in 2025 – multiplying more than 10 times since 2020. 💡 Global partners are voting with their #capital, placing big bets on Chinese biomedical #innovation. The pace suggests we're witnessing not just a #trend, but the birth of a new global #biopharma pillar. #ChineseInnovation #InnovativeDrug #licensing #BD #ChinaBiotech #Milestone #VCBeat

Is #China on the verge of a breakthrough in one of #ophthalmology's most complex surgical platforms? Our deep-dive reveals how the landscape for combined phaco-vitrectomy systems—long dominated by giants like Alcon and 博士伦 —is being reshaped in China. Driven by massive #funding rounds, #policy tailwinds, and maturing expertise, contenders like #SierraMedical, TowardPi , and #XiranHealth are advancing. Read our full #analysis and explore the #opportunity in this shifting market 👉 https://lnkd.in/e6zGeN-u #MedicalDevices #VC #HealthTech #SurgicalRobotics #vitrectomy #ChineseInnovation #VCBeat

💡Where is smart #capital flowing in China's #healthcare sector in September? #VCBeat's latest monthly ranking decodes the month's top #deals, most active #investors, and significant BD #transactions. Get the insights to navigate the market's evolution. https://lnkd.in/ee9M8uey #ChineseInnovation #Biotech #VC #assets #InvestmentTrend

The #GLP1 boom reshaped #WeightLoss. What's next? China's recent approval of compliant #FatDissolving injections marks a pivotal shift. ✅ The Breakthrough #Minova Pharma's Rongzhi® and Daewoong Pharmaceutical's V-OLET are China's first compliant injections, ending the long-standing market gap—starting with double chin treatment. ✅ The Momentum The R&D pipeline is accelerating. Companies like Sisram Medical and IMEIK Switzerland are advancing diverse candidates, exploring new mechanisms and expanding applications to areas like arms and waist. ✅ The Challenge Blockbuster status isn't guaranteed. Key hurdles include physician and #consumer education on the treatment's mechanism, and learning from the commercial experience of pioneers like #Kybella. Get our full analysis 👉 https://lnkd.in/ehcz5dsz #MedicalAesthetics #Biotech #ChinaInnovation #VCBeat

China Accelerator for Pharma & MedTech International Cooperation was officially launched in #Berlin on October 15 during the 2025 China (Chengdu)–Berlin Economic and Trade Cooperation Matchmaking Conference. 🎉 Jointly initiated by VCBeat and SPSI Cloud Port, under the guidance of the Chengdu Municipal Bureau of Expositions and the Chengdu Chamber of International Commerce, the Accelerator aims to support innovative Chinese #healthcare companies in growing globally, while helping international players tap into China's dynamic market. As China’s first media- and data-driven #GlobalServicePlatform for the healthcare industry, the Accelerator operates under a “Two Databases + One Platform” model: a database of over 180,000 Chinese #pharma and #medtech manufacturers connected with global distributors, investors, and clinical partners, alongside a platform that integrates data insights, brand communication, and partnership facilitation. #FutureOfHealthcare #GlobalHealth #MedicalInnovation

After revealing the "why" behind #NewCo in our precious video, now let's examine the "how" through a landmark #case: the Allist-ArriVent collaboration on #furmonertinib. Their #deal went beyond a simple license, creating a blueprint for global success. ✅ Equity & Upside: Shanghai Allist Pharmaceuticals Co., Ltd took equity in ArriVent Biopharma, aligning long-term interests and sharing in the full upside. ✅ Accelerated Execution: Furmonertinib rapidly gained #FDA Breakthrough Therapy status, speeding toward US approval. ✅ Massive Value Creation: ArriVent's #NASDAQ #IPO turned Allist's stake into a liquid, high-value asset. See the full case study on the latest #VBtalk 👇

What a day for China's #biotech #innovation! Five Chinese #innovators announced significant international partnerships in a 24-hour window. This flurry of activity underscores the growing global demand for China-born #biopharma #assets. ✅ Leads Biolabs & Dianthus Therapeutics, Inc. forged a ~$1B global pact (ex-China) for bispecific LBL-047 (DNTH212), including $38M in upfront/near-term payments. 👉 https://lnkd.in/eMZr2syq ✅ Shenzhen Pregene & Kite Pharma (a #Gilead company) entered a potential $1.64B global #collaboration for next-gen in vivo therapies, with a $120M upfront. 👉 https://lnkd.in/e6rcWbct ✅ Jiangsu Hansoh Pharmaceutical Group Co., Ltd. granted 罗氏制药 an exclusive worldwide license (ex-China) for its CDH17-targeting ADC HS-20106 in a deal worth up to $1.53B, including an $80M upfront. 👉 https://lnkd.in/efaYZSfw ✅ Aosaikang Pharmaceutical's subsidiary AskGene licensed ASKG712 to Visara for multiple Asian markets in a potential $96M deal, with a $7M upfront. 👉 https://lnkd.in/eSiy8Dvc ✅ Haihe Biopharma & Taiho Pharmaceutical Co., Ltd., announced an exclusive agreement for PI3Kα inhibitor risovalisib in Japan, with upfront and #milestone payments. 👉 https://lnkd.in/eVE3Trep #ChineseInnovation #BD #VCBeat

As the U.S. doubles down on #organoids —with the NIH launching a $87M Standardized Organoid Modeling Center to back the #FDA's push away from #animaltesting —a quiet revolution is building in China. Backed by a strong industrial chain and homegrown #innovation, China's organoid sector is positioned at the forefront of this global shift. Companies like Accurate International (创芯国际), 北京大橡科技有限公司, D1 Medical Technology (丹望医疗), Avatarget (艾玮得), K2 Oncology (科途医学), and bioGenous BIOTECH, Inc are turning scientific breakthroughs into real-world applications. Explore our in-depth analysis of the FDA's regulatory push and China's accelerating progress in the global shift 👉 https://lnkd.in/eS3F4akG #OrganOnAChip #DrugDevelopment #Biotech #Policy #ChinaInnovation #VCBeat

轩竹生物科技有限公司 is now trading on #HKEX. With a ~HKD 6B debut, it's the 17th Chinese #biotech to list in Hong Kong this year. This milestone validates a prescient multi-year #strategy by parent company Sihuan Pharmaceutical Holdings Group. By spinning off and empowering its innovative drug unit, Sihuan didn't just create a new listed entity—it successfully unlocked deep, latent value for the entire group. Explore the full analysis of this "H-spin-H" model here 👉 https://lnkd.in/eY8p2WhW #ChineseInnovation #ValueCreation #ChineseBiotech #IPO #Anaplazole #PPI